The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...
Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical ...
4d
Pharmaceutical Technology on MSNGoogle-backed Isomorphic Labs raises $600m to advance AI drug discoveryThe funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.
The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...
The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its ...
Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ...
AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...
AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding ...
Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These ...
Google spinoff Isomorphic Labs raised $600 million in its first external funding round as the company looks to apply ...
Since its launch, Isomorphic Labs has focused on using AI to model biological processes and accelerate drug discovery. The company co-developed AlphaFold 3 with Google DeepMind, an AI model ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results